The risk of SARS-CoV-2 outbreaks in low prevalence settings following the removal of travel restrictions

AUTHORS

R. Sachak-Patwa[1], H.M. Byrne[1], L. Dyson[2,3], R.N. Thompson[2,3,*]

*Correspondence to: robin.n.thompson@warwick.ac.uk

AFFILIATIONS

[1]Mathematical Institute, University of Oxford, Oxford, UK

[2]Mathematics Institute, University of Warwick, Coventry, UK

[3]Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick, Coventry, UK

ABSTRACT

Countries around the world have introduced travel restrictions to reduce SARS-CoV-2 transmission. As vaccines are gradually rolled out, attention has turned to when travel restrictions and other non-pharmaceutical interventions (NPIs) can be relaxed. Here, using SARS-CoV-2 as a case study, we develop a mathematical branching process model to assess the risk that, following the removal of NPIs, cases introduced into new locations initiate a local outbreak. Our model accounts for changes in background population immunity due to vaccination. We consider two locations in which the vaccine rollout has progressed quickly – specifically, the Isle of Man (a British crown dependency in the Irish Sea) and the country of Israel. Rather than aiming to make

exact quantitative predictions about the outbreak risk in different locations, we instead use data from these locations to demonstrate the general principle that the outbreak risk is unlikely to be eliminated completely when travel restrictions and other NPIs are removed in low prevalence settings. This conclusion holds even once vaccine programmes are completed. Key factors underlying these results are the potential for transmission even following vaccination, incomplete vaccine uptake, and the recent emergence of SARS-CoV-2 variants with increased transmissibility. Combined, these factors suggest that when travel restrictions are relaxed, it will still be necessary to implement surveillance of incoming passengers to identify infected individuals quickly. This measure, as well as tracing and testing (and/or isolating) contacts of detected infected passengers, should remain in place to suppress potential outbreaks until case numbers globally are reduced.

KEYWORDS

mathematical modelling; infectious disease epidemiology; outbreaks; non-pharmaceutical interventions; travel restrictions

1. INTRODUCTION

Combinations of non-pharmaceutical interventions (NPIs) have been introduced worldwide to counter the COVID-19 pandemic [1–3]. These measures include travel restrictions [4,5] and a range of other NPIs intended to reduce the numbers of contacts

between individuals [6]. The development and deployment of vaccines has also lowered transmission [7–10] and reduced the number of individuals experiencing clinical symptoms or severe disease once infected [11–13].

Effective NPIs have led to low levels of transmission in some locations. Australia and New Zealand have often been cited as examples of countries that have implemented NPIs effectively, with travel restrictions and quarantine of inbound travellers combined with short-term lockdowns and contact tracing to identify infected contacts whenever cases have been discovered [14–16]. Rigorous interventions targeted at inbound travellers in low prevalence settings reflect the fact that imported cases can contribute significantly to local incidence [17], and potentially initiate outbreaks with substantial local transmission [18,19]. At the time of writing (1st May 2021), Israel is the country that has vaccinated the largest proportion of its citizens, and the vaccination campaign there has been credited with reducing transmission [8], prompting some NPIs to be removed.

Despite the success of both NPIs and vaccines, the current overall picture is complicated. Vaccines do not prevent transmission entirely [7,20,21], and vaccine uptake is incomplete, particularly in some ethnic groups and in underserved communities [22]. Current tentative estimates suggest that first doses of the Pfizer and AstraZeneca SARS-CoV-2 vaccines are around 60% effective at preventing infection, with second doses leading to 65-85% effectiveness against infection [20]. Furthermore, the appearance of novel SARS-CoV-2 variants makes eliminating transmission more challenging. For example, the Alpha variant (B.1.1.7, or VOC 202012/01) that first

appeared in the United Kingdom in late 2020 has been found to be more transmissible than the SARS-CoV-2 virus that originally emerged in China [23]. Although public health measures have had some successes, these concerns raise a key question: Can NPIs such as travel restrictions be removed without any risk in low prevalence settings where vaccines have been distributed widely, or might outbreaks occur initiated by SARS-CoV-2 reimportations from elsewhere?

Epidemiological models are often used to assess the risk of outbreaks in scenarios in which the potential for pathogen transmission is not changing. According to the mathematical theory of branching processes, the probability that cases introduced into a new host population generate an outbreak driven by sustained local transmission is given by

$$\mathrm{Prob(outbreak)} = 1 - \left(\frac{1}{R}\right)^{I_0}, \qquad (1)$$

in which R is the reproduction number of the pathogen and I_0 is the number of introduced infectious cases. This expression had been used to assess the risks of outbreaks of pathogens including the Ebola virus [24–26], before being applied early in the COVID-19 pandemic to assess outbreak risks outside China [19]. Equation (1) reflects the risk that introduced cases generate an outbreak, and is based on a simple transmission model in which individuals are assumed to mix homogeneously and infected individuals are infectious for exponentially distributed time periods. Equation (1) also involves an assumption that pathogen transmissibility is fixed at its current level. In other words, the value of R is implicitly assumed to remain constant over the initial phase of the potential outbreak. With a background of rapidly changing population

immunity due to vaccination acting to reduce transmission, this assumption may not be accurate. To assess the risk of outbreaks if NPIs are removed during an ongoing vaccination campaign using branching process models, standard epidemiological modelling theory must be extended to account for temporally changing population immunity.

Here, we use branching processes to investigate whether an introduced case is likely to initiate an outbreak, accounting fully for temporal changes in population immunity due to an ongoing vaccination campaign. We use four metrics to assess the risk of an outbreak and consider two examples of vaccination campaigns from around the world, from the Isle of Man and the country of Israel. In both locations, vaccination is progressing quickly and prevalence is currently low. Given the relatively low numbers of cases in these locations during the pandemic, there is also likely to be a background of limited immunity from previous infections. We assess the risk of outbreaks in these places when travel restrictions and other NPIs are removed, considering scenarios in which NPIs are removed at different stages of the vaccination campaigns. Our goal is not to develop a detailed epidemiological model for estimating precise outbreak risk estimates. Instead, we use a simple model to show that, even when all vaccines have been deployed in low prevalence settings (i.e. a maximum vaccination proportion ν of individuals have been vaccinated, where the precise value of ν varies between locations), the combination of incomplete vaccine uptake, imperfect vaccination and variants of concern means that the risk of outbreaks due to imported cases will not be eliminated completely when NPIs are removed. This highlights the need for careful

monitoring of imported cases until global prevalence is reduced to low levels. Until vaccines are rolled out worldwide, there is still a risk of local transmission arising in low prevalence settings initiated by importations from elsewhere.

2. METHODS

Epidemiological model

We performed our main analyses using a stochastic branching process model that describes virus transmission in the initial stages of a potential outbreak. In this model, following the arrival of a case in the local population, new infections occur at rate $\beta(1 - \Lambda(t))$ and infected individuals have a mean infectious period of $1/\mu$ days (Fig 1a). The times between successive events in the model are assumed to follow exponential distributions. The function $\Lambda(t)$ reflects the extent to which transmission has been reduced by vaccination, where a value of $\Lambda(t) = 0$ corresponds to an entirely unvaccinated population. We consider scenarios in which travel restrictions and other NPIs are removed, and transmission is only limited by vaccine-acquired immunity.

To model an ongoing vaccination campaign, we set $\Lambda(t) = \eta_1 V_1(t - \alpha) + \eta_2 V_2(t - \alpha)$, where $V_1(t)$ is the proportion of individuals in the population who have received a single vaccine dose at time t and $V_2(t)$ is the proportion of individuals in the population who have received two vaccine doses at time t (Fig 1b). The parameters η_1 and η_2 reflect the effectiveness of the vaccine at preventing infection after one and two effective

doses, respectively (specifically, η_1 and η_2 represent the multiplicative reduction in susceptibility following one or two effective doses, compared to an unvaccinated individual, so that $0 \leq \eta_1 \leq \eta_2 \leq 1$), and the parameter α represents the delay between a vaccine dose being administered and being effective in the recipient. In our main analyses, since we are modelling relatively low prevalence settings, we do not consider immunity due to prior infections, although we present a supplementary analysis in which we demonstrate the robustness of our results to this assumption.

Under this model, the time-dependent reproduction number, accounting for any vaccines that have been administered and are effective at time t, is given by

$$R_V(t) = \frac{\beta(1 - \Lambda(t))}{\mu}. \qquad (2)$$

The value of $R_V(t)$ represents the expected number of secondary infections generated by a single infected individual in the population at time t, under the assumption that no further vaccinations take place in future. It is therefore representative of the "instantaneous" transmissibility at time t. Indeed, $R_V(t)$ is sometimes referred to as the instantaneous reproduction number [27–29]. In the absence of vaccination, so that $\Lambda(t) = 0$, then $R_V(t)$ is equal to the basic reproduction number, R_0.



Figure 1. The epidemiological model used in our analysis. (a) Following the introduction of an infected individual into the host population, local transmission may happen with infections occurring at rate $\beta(1-\Lambda(t))$, where $\Lambda(t)$ reflects the vaccination coverage in the local population. The mean infectious period of infected individuals is $1/\mu$ days. (b) The vaccination process is modelled by setting $\Lambda(t)$ according to the proportion of individuals in the population who have been vaccinated with one (V_1) or two (V_2) doses. The first vaccine dose is assumed to have effectiveness η_1 and the second vaccine dose has effectiveness η_2, where the values of η_1 and η_2 are the multiplicative reductions in the susceptibility of individuals who have been vaccinated with one or two vaccine doses, respectively (compared to an unvaccinated host). Vaccine doses are effective α days after they are administered. This leads to declining population susceptibility as a vaccine is rolled out across the population.

171 Vaccination data

172

173 In the model, $V_1(t)$ and $V_2(t)$ were set based on vaccination data from the location
174 under consideration (either the Isle of Man or Israel). Data describing the proportion of
175 the total population who had received one or two vaccine doses were available for the
176 periods up until 11th April 2021 (for the Isle of Man [30]) and 21st April 2021 (for Israel
177 [31]).

178

179 To explore how the risk of outbreaks is likely to change in future, we projected the
180 vaccine rollout forwards beyond these dates in the following way. We considered the
181 total population size of the location under consideration (denoted N), as well as the
182 numbers of individuals ($N_1(t)$ and $N_2(t)$) vaccinated with one or two doses, so that
183 $V_1(t) = N_1(t)/N$ and $V_2(t) = N_2(t)/N$. We assumed that a constant number of vaccine
184 doses are available each day in future (denoted D), and that there is a target period of τ
185 days between each vaccine dose. On any day in future, each available dose is assigned
186 to an individual who has been vaccinated with their first dose at least τ days ago, with
187 remaining doses then assigned to unvaccinated individuals. Resulting values of $N_1(t)$
188 and $N_2(t)$ were then converted to corresponding values of $V_1(t)$ and $V_2(t)$. To reflect the
189 fact that vaccine uptake is imperfect, and some population groups are not vaccinated,
190 we assumed that a maximum proportion ν of the population can ever be vaccinated.
191 Consequently, once the vaccination programme is completed, then $\Lambda(t) = \eta_2\nu$. The
192 value of ν varies between locations, and depends on factors such as the age
193 distribution of the host population. Since there is uncertainty in the vaccine uptake going

forwards, we conducted supplementary analyses in which we considered a range of different values of ν. Values of the model parameters used in the analyses in the main text for the Isle of Man and Israel are shown in Table 1.

Outbreak risk metrics

We used four different metrics to assess the risk that an infected individual, introduced into the population at time t, initiates an outbreak driven by sustained local transmission. The values of each of these metrics vary temporally. Each metric is used to estimate the risk that an imported case initiates an outbreak under the assumption that all travel restrictions and other NPIs are removed (in other words, pathogen transmissibility at time t is determined by $R_V(t)$, which represents an adjustment to the basic reproduction number R_0 due to vaccine-acquired immunity, as described above). An overview of the four metrics explored is provided here; additional details are available in the Supplementary Information.

The first metric we considered is the *Instantaneous Outbreak Risk (IOR)*. This quantity represents the expression shown in equation (1), with $R = R_V(t)$ and $I_0 = 1$. The IOR reflects the risk of an outbreak occurring starting from a single infected individual at time t, but under the assumption that the vaccine rollout does not continue after time t so that pathogen transmissibility is unchanged. While the IOR straightforward to calculate, it does not reflect changing population immunity due to vaccination over the initial phase of the potential outbreak. This standard metric is often used to assess the risk of

outbreaks in scenarios where pathogen transmissibility does not vary temporally [19,24–26,32–34].

The second metric is the *Case Outbreak Risk (COR)*. The COR is an extension of the IOR, accounting for changes in population susceptibility due to vaccination over the initial phase of the potential outbreak. The COR has previously been used to assess outbreak risks using branching processes for models in which pathogen transmission varies periodically [32,35–37]. Its calculation involves solving the differential equation

$$\frac{dq(t)}{dt} = \beta(1 - \Lambda(t))q(t)\big(1 - q(t)\big) + \mu(q(t) - 1). \qquad (3)$$

The COR at time t is then given by $1 - q(t)$, where $q(t)$ represents the probability of an outbreak failing to occur (i.e. ultimate extinction of the virus in the branching process model [38]) starting from a single infected individual introduced into the population at time t. Further details, including the derivation of equation (3), are provided in the Supplementary Information.

The third metric we considered is the *Simulated Outbreak Risk (SOR)*. The SOR involves repeated simulation of the branching process model, using the direct version of the Gillespie stochastic simulation algorithm [39] adapted to account for temporally varying pathogen transmissibility (due to changing population immunity). Simulations were run starting with a single infected individual introduced into the population at time t. The SOR then corresponds to the proportion of simulations in which a local outbreak occurs; an outbreak is said to occur if the total number of individuals infected

simultaneously exceeds a pre-defined threshold value, M. In our analyses, we set $M = 100$.

Finally, we consider the *Numerical Outbreak Risk (NOR)*. The NOR is analogous to the SOR, but with the advantage that it does not require large numbers of model simulations to be run. The NOR, therefore, also represents the risk that a single infected individual introduced into the population at time t initiates an outbreak in which at least $M = 100$ individuals are ever infected simultaneously.

Table 1: Default parameter values used in our analyses.

Parameter	Description	Value	Source
β	Transmission rate	Set so that $R_0 = \frac{\beta}{\mu}$ takes a prescribed value	Two scenarios were considered, with mean R_0 values of 3 (similar to the original SARS-CoV-2 variant [40]) and 5 (similar to the Alpha variant (B.1.1.7) [23])
$1/\mu$	Duration of infectiousness	5 days	[41]
α	Delay between a vaccine dose being administered and being effective	14 days	[42]
η_1	Multiplicative reduction in susceptibility of an individual vaccinated with a single effective dose (compared to an unvaccinated host)	0.6	[20]
η_2	Multiplicative reduction in susceptibility of an individual vaccinated with two effective doses (compared to an unvaccinated host)	0.85	[20]
ν	Vaccine uptake	0.8 (Isle of Man) and 0.7 (Israel). Other values are	[43]

		considered in the Supplementary Information	
N	Total population size	84,500 (Isle of Man) and 8,772,800 (Israel)	[44]
D	Number of vaccine doses available each day (in future projections)	1,000 (Isle of Man) and 56,000 (Israel)	Average number of doses administered each day in the previous 30 days (up to 11 April 2021 for Isle of Man [30] and 21 April 2021 for Israel [31])
τ	Target period between vaccine doses (in future projections)	84 days (Isle of Man) and 21 days (Israel)	[45,46]

3. RESULTS

As described in the Methods, we first generated projections of the number of vaccinated individuals in future for the Isle of Man (Fig 2a) and Israel (Fig 2d), based on past vaccination data in those locations. To explore the impact of vaccination on virus transmission, we calculated the time-dependent reproduction number ($R_V(t)$; equation (2)) throughout the vaccination campaigns. We considered two different scenarios. In the first, we set the mean value of R_0 (i.e. the reproduction number in the absence of vaccination) equal to 3, as was the situation early in the COVID-19 pandemic (Fig 2b,e). In the second scenario, we set the mean value of R_0 equal to 5 (Fig 2c,f) to reflect the fact that currently circulating SARS-CoV-2 variants are more transmissible than the original virus [23]. This second scenario is therefore likely to be a more realistic reflection of the current and future risk.



Figure 2. Effect of vaccination on population susceptibility. (a) The proportion of the population of the Isle of Man that is unvaccinated $(1 - V_1(t) - V_2(t))$, vaccinated with a single dose $(V_1(t))$ and vaccinated with two doses $(V_2(t))$. The period in which vaccination data were available is shown in white, and the period in which vaccination data were projected is shown in purple. (b) The time-dependent reproduction number $(R_V(t))$ corresponding to the vaccination data in panel a, starting from a mean initial value of $R_V(0) = R_0 = 3$. To account for uncertainty in the value of R_0, a normal distribution was assumed about the mean value of R_0 with variance $\sigma^2 = 0.25$, which is reflective of the range of R_0 values estimated early in the COVID-19 pandemic [40]. (c) Analogous to panel b but starting from a mean initial value of $R_V(0) = R_0 = 5$. (d)-(f) Analogous to panels a-c but using vaccination data for Israel. In all panels, $t = 0$ days corresponds to 18th December 2020. Ticks on the x-axes refer to the starts of the months labelled. Parameter values are shown in Table 1.

We then calculated the values of the four different outbreak risk metrics throughout the period considered (18th December 2020 to 20th August 2021) based on these vaccination projections (Fig 3). This involves a scenario in which NPIs are removed

entirely, so that $R_V(t)$ is not reduced by interventions other than vaccination. These metrics then reflect the risk that a single case first entering into the population at the date of introduction shown initiates an outbreak driven by sustained local transmission, given that no NPIs are in place. For each metric, and each time during the vaccination programme, we calculated the outbreak risk by integrating over the full distribution for $R_V(t)$ shown in Fig 2. In practice, the precise value of $R_V(t)$ is not known exactly at any time: the purpose of this integration (which is over values of $R_V(t)$, rather than values of t) is to account for this uncertainty in outbreak risk estimates. The resulting outbreak risk therefore represents a point estimate of the risk accounting for uncertainty in pathogen transmissibility.

The IOR represents the probability of sustained local transmission based only on the value of $R_V(t)$ at the precise instance that the virus is introduced into the population. When an introduction occurs while a vaccine is being deployed, there is a background of decreasing population susceptibility, and so $R_V(t)$ may in fact decrease over the initial stages of a potential outbreak. For that reason, it is unsurprising that the IOR sometimes overestimates the outbreak risk compared to the other risk metrics (see e.g. black lines in Fig 3a,c – and see Discussion).

In contrast, we found close agreement between the COR, SOR and NOR. Due to the high assumed vaccine uptake in the Isle of Man, the outbreak risk at the end of the vaccination programme there was calculated to be lower than when the vaccine rollout was completed in Israel (although we also considered supplementary analyses with

different assumed vaccine uptake values – Fig S1). In the first scenario that we considered (mean $R_0 = 3$), which is representative of the transmissibility of the original SARS-CoV-2 virus, the outbreak risk was projected to be low following the vaccination programme in the Isle of Man.

However, when the virus was assumed to be more transmissible (mean $R_0 = 5$), as is the case for newly emerged variants of concern such as the Alpha variant (B.1.1.7), the outbreak risk was found to be substantial even following the projected end of the vaccination campaigns in both the Isle of Man and Israel. For example, when the assumed vaccine uptake values of $\nu = 0.8$ and $\nu = 0.7$ had been achieved in the Isle of Man and Israel, respectively, the NOR took values of 0.37 (95% Equal-Tailed Credible Interval (CrI): [0.22,0.48], calculating using the 95% Equal-Tailed CrI for $R_V(t)$ at the end of the vaccination rollout) and 0.51 (95% Equal-Tailed CrI: [0.39,0.59]) in those locations. Given the uncertainty in epidemiological modelling projections, the key point to note is that these values are greater than zero (rather than the exact outbreak risk estimates themselves), suggesting that outbreaks can still occur when NPIs are removed following the completion of vaccination programmes. This result is robust to a range of assumptions surrounding virus transmission and the effectiveness of vaccines (see Supplementary Information).



Figure 3. The risk that an infectious case introduced at each stage of the vaccination campaign initiates an outbreak, if travel restrictions and other NPIs are removed. (a) The outbreak risk assessed using the four metrics (IOR – black; COR – blue dashed; SOR – green dots; NOR – red), based on vaccination data from the Isle of Man and assuming mean $R_0 = 3$, as in Fig 2b. The period in which vaccination data were available is shown in white, and the period in which vaccination data were projected is shown in purple. (b) Analogous to panel a but with mean $R_0 = 5$ (see Fig 2c). (c) Analogous to panel a but using vaccination data for Israel (see Fig 2e). (d). Analogous to panel a but using vaccination data for Israel with mean $R_0 = 5$ (see Fig 2f). Ticks on the x-axes refer to the starts of the months labelled. Parameter values are shown in Table 1.

4. DISCUSSION

As vaccines are administered in countries around the world, attention has turned to the possibility that transmission will soon be reduced to the extent that travel restrictions and other NPIs can be relaxed. Here, we have investigated the impact of removing NPIs on the risk of outbreaks occurring in locations with low prevalence and a significant proportion of the population vaccinated. We used four metrics to estimate the risk that a case introduced at any stage in the vaccination rollout leads to an outbreak driven by local transmission, in a scenario in which NPIs are removed. We calculated temporal changes in the values of these metrics in the context of vaccination in the Isle of Man and in Israel, two locations with low prevalence and vaccination campaigns that have progressed quickly.

We found that vaccination is leading to a substantial drop in the potential for virus transmission in both the Isle of Man and Israel, as indicated by a decreasing value of the time-dependent reproduction number, $R_V(t)$ (Fig 2). However, even when the vaccine rollout is completed (with 80% of individuals fully vaccinated in the Isle of Man, and 70% in Israel; other values are considered in the Supplementary Information), the combination of vaccines not preventing transmission entirely, incomplete vaccine uptake and the emergence of novel SARS-CoV-2 variants suggests that the risk of outbreaks initiated by infected individuals arriving from elsewhere will not be eliminated when NPIs are removed (Fig 3). This conclusion holds unless the vaccine uptake is very high (Fig S1). This suggests that, when NPIs such as travel restrictions are relaxed, it

will still be advisable to be aware of the potential for local transmission. Ensuring that case numbers are reduced elsewhere (i.e. in locations that imported cases might travel from) will reduce the risk of importations, and strategies should be considered to suppress outbreaks quickly if importations occur.

One potential use of our modelling framework by policy-makers is to identify the dates on which travel restrictions can be relaxed, based on a maximum acceptable outbreak risk. As an example, if the maximum acceptable value of the NOR is 0.4, then our analysis with $R_0 = 5$ suggests that travel restrictions can be lifted on the Isle of Man at the end of July 2021 (Fig 3b; the first date on which the NOR is projected to fall below 0.4 in our illustrative analysis is 29th July 2021). However, as described above, since the risk of local transmission following introductions remains, it will be necessary to continue to monitor inbound passengers in low prevalence settings to identify infected individuals, even once vaccination programmes are completed.

Our modelling approach for assessing outbreak risks was motivated by studies in which the potential for pathogen transmission varies periodically [32,35–37,47–50], due, for example, to seasonal changes in weather conditions that affect transmission. In that context, Carmona and Gandon [35] describe a “winter is coming effect”, in which the risk of an outbreak is lower than current environmental conditions suggest if conditions become less favourable for transmission in the near future. In the terminology used in our manuscript, if current environmental conditions promote pathogen transmission, then the IOR is expected to be high. This is because the IOR reflects the outbreak risk

382 based on the conditions at the precise instance when the virus is introduced into the
383 population. However, if environmental conditions are expected to become less
384 favourable for transmission in the near future, then the values of the other risk metrics
385 are lower than the IOR, since those metrics account for changes in transmissibility over
386 the initial phase of the potential outbreak. Although in general we found a close
387 agreement between the four metrics that we considered, a background of decreasing
388 population susceptibility can lead to a similar effect in which the IOR is larger than the
389 COR, SOR or NOR (e.g. Fig 3a,c).
390
391 In this study, we used a simple branching process model to investigate the risk of
392 outbreaks when NPIs are removed during a vaccination programme. This involved
393 considering whether introduced cases are likely to lead to sustained local transmission
394 or instead fade out without causing an outbreak. We made the standard branching
395 process modelling assumption that population immunity is unaffected by infections in
396 the earliest stages of potential outbreaks [19,24–26,51,52]. In other words, infection-
397 acquired immunity following the arrival of the pathogen in the host population is not
398 considered. While this is reasonable when case numbers are low in the initial stages of
399 potential outbreaks, a more detailed model is needed to explore other quantities, such
400 as the eventual size of outbreaks. Following a vaccination programme, outbreaks are
401 likely to be smaller than those that occur before vaccines are widely administered.
402
403 Another simplification of our model is that we only accounted for changes in population
404 susceptibility due to the vaccine rollout. We did not account for prior immunity of some

members of the population due to previous exposures to the virus. At the time of writing (1st May 2021), there have been 1,154 confirmed cases in the Isle of Man and 838,000 confirmed cases in Israel. Since these case numbers correspond to a relatively small proportion of the host population (representing 1.4% and 9.6% of the population in the Isle of Man and Israel, respectively), we do not expect this assumption to affect our key findings. Furthermore, immunity is likely to wane over time [53–55], reducing the effect of previous exposures on the outbreak risk. To test the potential impact of infection-acquired immunity arising from cases occurring before May 2021, we also conducted a supplementary analysis in which the value of R_0 is reduced by 1.4% in the Isle of Man and 9.6% in Israel, and we found qualitatively similar results (Fig S2): even in this "best case" scenario, there is still a risk of outbreaks due to imported cases once the vaccination programmes are completed. Importantly, in other countries in which higher numbers of cases have occurred, prior immunity may play a larger role in reducing the risk of outbreaks compared to the low prevalence settings considered here. Understanding the extent of this effect, based on the rate at which immunity wanes, is an important target for further study.

In this research, we assumed that vaccines reduce transmission by lowering the probability that a vaccinated host becomes infected compared to an unvaccinated host. Two effective vaccine doses were assumed to reduce the probability of infection substantially (by $\eta_2 = 0.85$), which is in line with estimates for the Pfizer vaccine used in the UK Government's COVID-19 roadmap modelling [20]. However, there is uncertainty about the precise level of protection offered by different COVID-19 vaccines. For that

428 reason, we also conducted a supplementary analysis (Fig S3) in which we considered a
429 range of values of η_2. In every scenario that we explored, the risk of outbreaks following
430 the completion of vaccination programmes in low prevalence settings was greater than
431 zero, with larger outbreak risks for lower values of η_2.
432
433 In addition to reducing the risk that a host becomes infected as assumed here [56],
434 vaccination may also reduce the risk of onwards transmission following infection [7],
435 reduce the risk of severe disease developing, or a combination of these effects [57]. In
436 principle, it would be possible to develop a more complex model that accounts for all of
437 these effects separately, at the cost of having to estimate (or assume) values of the
438 associated parameter values. It would also be possible to develop a transmission model
439 in which either vaccine- and/or infection-acquired immunity wanes. There is currently
440 significant uncertainty about the extent and speed of waning immunity, with hope that
441 antibody responses and/or cellular immune responses may provide long-lasting immune
442 memory, at least in some individuals [58,59]. Booster vaccination for vulnerable
443 individuals is currently being considered in several high-income countries, given the
444 possibility that vaccine-acquired immunity may wane. We note that any waning of
445 immunity will act to enhance our main qualitative conclusion that the risk of outbreaks is
446 unlikely to be eliminated completely in low prevalence settings by vaccination
447 programmes.
448
449 Other factors that may merit consideration in further analyses of future outbreak risks
450 include the impact of population-structure on both vaccine effectiveness [60] and

transmission [61,62], and the possibility that individuals' behaviours may be different following the pandemic compared to beforehand, even when NPIs and travel restrictions are removed. For precise quantitative outbreak risk predictions to be made, it may be necessary to estimate R_0 in different locations. It would also be necessary to incorporate changes in R_0 due to further new variants in our analyses, although we note that any increase in transmissibility will act to strengthen our main conclusion that vaccine-acquired immunity alone is unlikely to be sufficient to prevent outbreaks. Another important consideration is the degree of heterogeneity in transmission between different infected individuals. For a range of pathogens, including SARS-CoV-2, the majority of transmissions are generated by a relatively small proportion of infectious hosts [63–65]. We therefore also conducted a supplementary analysis in which we considered the dependence of outbreak risk estimates following the completion of vaccination programmes in the Isle of Man and Israel on the assumed individual-level variation in SARS-CoV-2 transmission. While a higher degree of heterogeneity (i.e. a higher probability of "superspreading" events) acts to lower the outbreak risk, in each scenario explored outbreaks were still possible in low prevalence settings following vaccination programmes when NPIs are removed (Fig S4).

To summarise, our analyses have demonstrated the general principle that, even following vaccination programmes in low prevalence settings, the risk of outbreaks remains when NPIs are removed. Our intention is not to argue that travel restrictions and other NPIs should not be relaxed once vaccination programmes are sufficiently advanced, but rather that measures should be taken to ensure that any clusters of

cases are suppressed quickly if they arise. A local outbreak requires two steps: first, the virus must be imported from elsewhere; second, local transmission must occur. The first step emphasises the need for a global approach to minimising transmission, since higher case numbers at a potential source location translate into a higher importation risk. The second step emphasises the need to ensure that, while vaccination acts to reduce transmission substantially, continued surveillance of inbound passengers for infection, combined with isolation and/or testing of contacts of detected infected individuals, is important when travel restrictions and other NPIs are relaxed. These measures are necessary, since only once the global prevalence of SARS-CoV-2 infections is reduced substantially can the risk of outbreaks in low prevalence settings be eliminated.

COMPETING INTERESTS

We have no competing interests.

DATA ACCESSIBILITY

All data required to reproduce the results presented here are available at https://github.com/robin-thompson/Outbreaks_Low_Prevalence_Settings/. Data are also shown in Figs 2a and 2d. No restrictions exist on data availability.

CODE AVAILABILITY STATEMENT

All code required to reproduce the results presented here are available at https://github.com/robin-thompson/Outbreaks_Low_Prevalence_Settings/, along with relevant documentation.

AUTHORS' CONTRIBUTIONS

Conceptualization: RS-P, RNT, LD; Methodology: RS-P, RNT; Investigation: RS-P; Supervision: RNT, HMB; Writing – original draft: RNT, RS-P; Writing – review and editing: All authors.

FUNDING

RS-P is supported by the EPSRC through the Centre for Doctoral Training in Industrially Focussed Mathematical Modelling at the University of Oxford (grant EP/L015803/1), in collaboration with Biosensors Beyond Borders Ltd. LD was supported by the MRC through the COVID-19 Rapid Response Rolling Call (grant MR/V009761/1) and by UKRI through the JUNIPER modelling consortium (grant MR/V038613/1). The funders had no role in study design, data collection and analysis, preparation of the manuscript or the decision to publish.

ACKNOWLEDGEMENTS

We thank members of the Wolfson Centre for Mathematical Biology (University of Oxford) and the Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (University of Warwick) for helpful discussions about this work. We also thank

the two anonymous reviewers, and Ed Hill, for helpful feedback that enabled us to improve this manuscript.

REFERENCES

1. Liu Y, Morgenstern C, Kelly J, Lowe R, Jit M. The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories. BMC Med. 2021;19: 40.
2. Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. Lancet. 2020;395: 1382–1393.
3. Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Heal. 2020;4: 397–404.
4. Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science (80-). 2020;368: 395–400.
5. Daon Y, Thompson RN, Obolski U. Estimating COVID-19 outbreak risk through air travel. J Travel Med. 2020;27: taaa093.
6. Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, et al. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic

540 in Wuhan, China: a modelling study. Lancet Public Heal. 2020;5: e261–e270.
541 7. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Impact of
542 vaccination on household transmission of SARS-COV-2 in England. medRxiv.
543 2021.
544 8. Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. COVID-19 dynamics
545 after a national immunization program in Israel. Nat Med. 2021.
546 9. Shah AS, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R, et al. Effect of
547 vaccination on transmission of COVID-19: an observational study in healthcare
548 workers and their households. medRxiv. 2021.
549 10. Richterman A, Meyerowitz EA, Cevik M. Indirect protection by reducing
550 transmission: Ending the pandemic with SARS-CoV-2 vaccination. Open Forum
551 Infect Dis. 2021; ofab259.
552 11. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety
553 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383.
554 12. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.
555 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-
556 CoV-2: an interim analysis of four randomised controlled trials in Brazil, South
557 Africa, and the UK. Lancet. 2021;397.
558 13. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and
559 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384.
560 14. Baker MG, Wilson N, Blakely T. Elimination could be the optimal response
561 strategy for covid-19 and other emerging pandemic diseases. BMJ. 2020;371.
562 15. Huang QS, Wood T, Jelley L, Jennings T, Jefferies S, Daniells K, et al. Impact of

563 the COVID-19 nonpharmaceutical interventions on influenza and other respiratory
564 viral infections in New Zealand. Nat Commun. 2021;12.
565 16. Baker MG, Wilson N, Anglemyer A. Successful elimination of Covid-19
566 transmission in New Zealand. N Engl J Med. 2020;383.
567 17. Russell TW, Wu JT, Clifford S, Edmunds WJ, Kucharski AJ, Jit M, et al. Effect of
568 internationally imported cases on internal spread of COVID-19: a mathematical
569 modelling study. Lancet Public Heal. 2021;6: e12-20.
570 18. Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility
571 of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet
572 Glob Heal. 2020;8: e488–e496.
573 19. Thompson RN. Novel coronavirus outbreak in Wuhan, China, 2020: Intense
574 surveillance is vital for preventing sustained transmission in new locations. J Clin
575 Med. 2020;9: 498.
576 20. Keeling MJ, Moore S, Dyson L, Tildesley MJ, Hill EM. Road map scenarios and
577 sensitivity. 2021. Available:
578 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/atta
579 chment_data/file/975911/S1184_SPI-
580 M_University_of_Warwick_Road_Map_Scenarios_and_Sensitivity.pdf
581 21. Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ. Vaccination and non-
582 pharmaceutical interventions for COVID-19: a mathematical modelling study.
583 Lancet Infect Dis. 2021;S1473-3099: 00143–2.
584 22. Razai MS, Osama T, McKechnie DGJ, Majeed A. Covid-19 vaccine hesitancy
585 among ethnic minority groups. BMJ. 2021.

586 23. Davies N, Abbott S, Barnard R, Jarvis C, Kucharski A, Munday J, et al. Estimated
587 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science
588 (80-). 2021.
589 24. Althaus CL, Low N, Musa EO, Shuaib F, Gsteiger. Ebola virus disease outbreak
590 in Nigeria: Transmission dynamics and rapid control. Epidemics. 2015;11: 80–84.
591 25. Thompson RN, Gilligan CA, Cunniffe NJ. Detecting presymptomatic infection is
592 necessary to forecast major epidemics in the earliest stages of infectious disease
593 outbreaks. PLoS Comput Biol. 2016;12: e1004836.
594 26. Merler S, Ajelli M, Fumanelli L, Parlamento S, y Piontti AP, Dean NE, et al.
595 Containing Ebola at the source with ring vaccination. PLoS Negl Trop Dis.
596 2016;10: e0005093.
597 27. Fraser C. Estimating individual and household reproduction numbers in an
598 emerging epidemic. PLoS One. 2007;2: e758.
599 28. White LF, Moser CB, Thompson RN, Pagano M. Statistical estimation of the
600 reproductive number from case notification data. Am J Epidemiol. 2020; kwaa211.
601 29. Thompson RN, Stockwin JE, Gaalen RD Van, Polonsky JA, Kamvar ZN, Demarsh
602 PA, et al. Improved inference of time-varying reproduction numbers during
603 infectious disease outbreaks. Epidemics. 2019;19: 100356.
604 30. Isle of Man Government. COVID-19 Vaccination Programme. 2021 [cited 15 Apr
605 2021]. Available: https://covid19.gov.im/about-coronavirus/open-data-downloads/
606 31. Our World in Data. Coronavirus (COVID-19) vaccinations. 2021 [cited 23 Apr
607 2021]. Available: https://ourworldindata.org/covid-vaccinations
608 32. Bromiley J, Hart WS, Iwami S, Thompson RN. Assessing the threat from

609 emerging infectious diseases in seasonally varying environments. preprint. 2021.
610 33. Keeling MJ, Rohani P. Modeling infectious diseases in humans and animals.
611 Princeton University Press; 2008.
612 34. Thompson RN, Gilligan CA, Cunniffe NJ. Will an outbreak exceed available
613 resources for control? Estimating the risk from invading pathogens using practical
614 definitions of a severe epidemic. J R Soc Interface. 2020;17: 20200690.
615 35. Carmona P, Gandon S. Winter is coming: Pathogen emergence in seasonal
616 environments. PLoS Comput Biol. 2020;16: e1007954.
617 36. Ball FG. The threshold behaviour of epidemic models. J Appl Probab. 1983;20:
618 227–241.
619 37. Bacaër N, Ait Dads EH. On the probability of extinction in a periodic environment.
620 J Math Biol. 2014;68: 533–548.
621 38. Kendall DG. On the generalized “birth-and-death” process. Ann Math Stat.
622 1948;19: 1–15.
623 39. Gillespie DT. Exact stochastic simulation of coupled chemical reactions. J Phys
624 Chem. 1977;8: 2340–2361.
625 40. Billah MA, Miah MM, Khan MN. Reproductive number of coronavirus: A
626 systematic review and meta-analysis based on global level evidence. PLoS One.
627 2020;15.
628 41. Kucharski AJ, Klepac P, Conlan AJK, Kissler SM, Tang ML, Fry H, et al.
629 Effectiveness of isolation, testing, contact tracing, and physical distancing on
630 reducing transmission of SARS-CoV-2 in different settings: a mathematical
631 modelling study. Lancet Infect Dis. 2020;20.

632 42. Centers for Disease Control and Prevention. Interim public health
633 recommendations for fully vaccinated people. 2021.
634 43. Sallam M. Covid-19 vaccine hesitancy worldwide: A concise systematic review of
635 vaccine acceptance rates. Vaccines. 2021.
636 44. Worldometer. Current world population. 2021 [cited 21 Apr 2021]. Available:
637 https://www.worldometers.info/world-population/
638 45. Isle of Man Government. Frequently asked questions about the vaccine. 2021.
639 46. Wise J. Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel,
640 shows peer reviewed study. BMJ. 2021;372.
641 47. Klein B, MacDonald PDM. The multitype continuous-time Markov branching
642 process in a periodic environment. Adv Appl Probab. 1980;12: 81–93.
643 48. Jagers P, Nerman O. Branching processes in periodically varying environment.
644 Ann Probab. 1985;13: 254–268.
645 49. Nipa KF, Allen LJS. Disease emergence in multi-patch stochastic epidemic
646 models with demographic and seasonal variability. Bull Math Biol. 2020;82: 152.
647 50. Bacaër N, Ed-Darraz A. On linear birth-and-death processes in a random
648 environment. J Math Biol. 2014;69: 73–90.
649 51. Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility
650 of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet
651 Glob Heal. 2020;8: E488-496.
652 52. Lovell-Read FA, Funk S, Obolski U, Donnelly CA, Thompson RN. Interventions
653 targeting non-symptomatic cases can be important to prevent local outbreaks:
654 SARS-CoV-2 as a case study. J R Soc Interface. 2021;18: 20201014.

655 53. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd
656 immunity to SARS-CoV-2 infection by mass vaccination. The Lancet. 2020. p.
657 10263.
658 54. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the
659 transmission dynamics of SARS-CoV-2 through the postpandemic period.
660 Science (80-). 2020;368: 860–868.
661 55. Crellen T, Pi L, Davis EL, Pollington TM, Lucas TCD, Ayabina D, et al. Dynamics
662 of SARS-CoV-2 with waning immunity in the UK population. Philos Trans R Soc B
663 Biol Sci. 2021;376: 20200274.
664 56. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al.
665 Impact of vaccination on SARS-CoV-2 cases in the community: a population-
666 based study using the UK's COVID-19 Infection Survey. medRxiv.
667 57. Gog JR, Hill EM, Danon L, Thompson RN. Vaccine escape in heterogeneous
668 populations: insights for SARS-CoV-2 from a simple model. medRxiv. 2021.
669 58. Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, et al. Robust SARS-
670 CoV-2-specific T cell immunity is maintained at 6 months following primary
671 infection. Nat Immunol. 2021;22: 620–626.
672 59. Tea F, Stella AO, Aggarwal A, Darley DR, Pilli D, Vitale D, et al. SARS-CoV-2
673 neutralizing antibodies: longevity, breadth, and evasion by emerging viral variants.
674 PLoS Med. 2021;18: e1003656.
675 60. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-
676 informed COVID-19 vaccine prioritization strategies by age and serostatus.
677 Science (80-). 2021;371.

678 61. Britton T, Ball F, Trapman P. A mathematical model reveals the influence of
679 population heterogeneity on herd immunity to SARS-CoV-2. Science (80-). 2020.
680 62. Davies NG, Klepac P, Liu Y, Prem K, Jit M, CMMID COVID-19 Working Group, et
681 al. Age-dependent effects in the transmission and control of COVID-19 epidemics.
682 Nat Med. 2020.
683 63. Thompson RN, Hollingsworth TD, Isham V, Arribas-Bel D, Ashby B, Britton T, et
684 al. Key questions for modelling COVID-19 exit strategies. Proc R Soc B Biol Sci.
685 2020;287: 20201405.
686 64. Endo A, CMMID COVID-19 working group, Abbott S, Kucharski AJ, Funk S.
687 Estimating the overdispersion in COVID-19 transmission using outbreak sizes
688 outside China. Wellcome Open Res. 2020;5: 67.
689 65. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect
690 of individual variation on disease emergence. Nature. 2005;438: 355–359.
691